Allogene Therapeutics, Inc. ALLO 深 滬
等待開盤 07-06 09:30:00 美东时间
2.08
-0.030
-1.42%
華盛通- 最 高2.18
- 今 開2.13
- 成交量 913.63万股
- 最 低 2.03
- 昨 收 2.11
- 總市值 7.18亿
- 52周最高 4.46
- 市盈率 靜 --
- 換手率 2.65%
- 52周最低 0.9842
- 委 比 25.92%
- 總股本 3.45亿
- 歷史最高 55.00
- 量 比 0.57
- 振 幅 7.11%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell th...
07-01 21:05
Allogene Launches ATM Offering to Bolster Capital Flexibility
Allogene Therapeutics ( ($ALLO) ) has issued an update. At its June 18, 2026 an...
06-23 04:54
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics reported positive interim data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101, a TCR-T therapy for preventing relapse in patients with hematologic malignancies after allo-HCT. Of 14 patients who received TSC-101, 11 achieved complete donor chimerism within three weeks, and two additional patients showed improving chimerism. The therapy was well-tolerated, with safety consistent with post-HCT adverse events. The company ...
06-22 11:00
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
An announcement from Cellectis SA ( ($CLLS) ) is now available. On June 9, 2026...
06-10 05:09
Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
06-08 18:34
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics highlighted promising clinical and safety data for AlloNK, an allogeneic NK cell therapy, in treating refractory autoimmune diseases at the EULAR 2026 Congress. AlloNK, combined with rituximab, showed robust responses across 31 patients with rheumatoid arthritis (RA), Sjögren disease (SjD), and systemic sclerosis (SSc). RA data demonstrated a 71% ACR50 response at six months in a Phase 2a trial, with durable responses in hi...
06-08 10:30
Allogene Therapeutics names Zachary Roberts CEO in planned succession
Allogene Therapeutics (ALLO) said on Thursday that CEO David Chang will step down effective June 30 after eight years leading the company and will remain on its board of directors. The company named Z...
05-29 05:29
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced that Dr. David Chang will transition from CEO to continue serving on the Board of Directors. Dr. Zachary Roberts, currently EVP, R&D and CMO, will succeed him as President and CEO effective July 1, 2026. Dr. Chang's leadership established Allogene as a leader in allogeneic CAR T therapies, advancing innovative treatments and infrastructure. Dr. Roberts has reshaped the company's clinical strategy, driving advanceme...
05-28 21:02
Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with
05-20 04:07
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics will present data at the EULAR 2026 Congress on their AlloNK therapy combined with rituximab, showing comparable efficacy to CAR T-cell therapy in autoimmune diseases. Highlights include 71% ACR50 response in refractory rheumatoid arthritis, successful treatment of severe Sjögren's disease, deep B-cell depletion, and a favorable safety profile. A live webcast with Dr. Paul Emery will discuss these findings on June 8, 2026.
05-19 20:05
